GILD News 71.60 04/21/2014 21:17:36 Gilead Sciences (GILD)
Post# of 273318
Posted On: 04/21/2014 10:17:37 PM
Gilead Sciences (GILD) 71.60 $GILD
Gilead Sovaldi Drug Sales Key In Q1 Earnings Report
at Investor's Business Daily - Mon Apr 21, 5:34PM CDT
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences' (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday....
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Most active Nasdaq-traded stocks
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Stocks Rise; Valeant, Netflix Soar After Hours
at Investor's Business Daily - Mon Apr 21, 4:00PM CDT
Stocks rose Monday, with the S&P 500 notching its fifth straight gain, as quarterly earnings reports continue to roll out. Valeant Pharmaceuticals (VRX) soared in post-session trading after The Wall Street Journal reported that the Canadian drugmaker...
SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 2.29% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.40 to a high of $71.99. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $70.64 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.29%
Comtex SmarTrend(R) - Mon Apr 21, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.40 to a high of $71.99. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $70.64 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA
Business Wire - Mon Apr 21, 3:30PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. The FDA has set target review dates under the Prescription Drug User Fee Act (PDUFA) of October 3, 2014 for cobicistat and October 4, 2014 for elvitegravir.
Gilead Q1 Its First Full Quarter With Sovaldi
at Investor's Business Daily - Mon Apr 21, 12:44PM CDT
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences' (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday....
Gilead Sciences (GILD) Breaks Through Resistance at $70.73
Comtex SmarTrend(R) - Mon Apr 21, 12:29PM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $69.91 and have already reached the first level of resistance at $70.73. Analysts will be watching for a cross of the next upside pivot targets of $71.46 and $73.01.
Midday Glance: Biotechnology companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Will This Report Help Gilead Sciences (GILD) Stock Today?
at The Street - Mon Apr 21, 11:31AM CDT
Gilead Sciences (GILD) has an estimated total return of 45.4% according to a research note published by Citigroup.
Jim Cramer: We're Still in the Tech Woods
at The Street - Mon Apr 21, 10:25AM CDT
When people attach such frothy numbers to IPOs, we have problems.
Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes
Early Glance: Biotechnology companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie and Merck around the corner. In the...
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...
Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Gilead Sovaldi Drug Sales Key In Q1 Earnings Report
at Investor's Business Daily - Mon Apr 21, 5:34PM CDT
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences' (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday....
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Most active Nasdaq-traded stocks
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Stocks Rise; Valeant, Netflix Soar After Hours
at Investor's Business Daily - Mon Apr 21, 4:00PM CDT
Stocks rose Monday, with the S&P 500 notching its fifth straight gain, as quarterly earnings reports continue to roll out. Valeant Pharmaceuticals (VRX) soared in post-session trading after The Wall Street Journal reported that the Canadian drugmaker...
SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 2.29% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.40 to a high of $71.99. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $70.64 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.29%
Comtex SmarTrend(R) - Mon Apr 21, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.40 to a high of $71.99. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $70.64 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA
Business Wire - Mon Apr 21, 3:30PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. The FDA has set target review dates under the Prescription Drug User Fee Act (PDUFA) of October 3, 2014 for cobicistat and October 4, 2014 for elvitegravir.
Gilead Q1 Its First Full Quarter With Sovaldi
at Investor's Business Daily - Mon Apr 21, 12:44PM CDT
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences' (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday....
Gilead Sciences (GILD) Breaks Through Resistance at $70.73
Comtex SmarTrend(R) - Mon Apr 21, 12:29PM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $69.91 and have already reached the first level of resistance at $70.73. Analysts will be watching for a cross of the next upside pivot targets of $71.46 and $73.01.
Midday Glance: Biotechnology companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Will This Report Help Gilead Sciences (GILD) Stock Today?
at The Street - Mon Apr 21, 11:31AM CDT
Gilead Sciences (GILD) has an estimated total return of 45.4% according to a research note published by Citigroup.
Jim Cramer: We're Still in the Tech Woods
at The Street - Mon Apr 21, 10:25AM CDT
When people attach such frothy numbers to IPOs, we have problems.
Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes
Early Glance: Biotechnology companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie and Merck around the corner. In the...
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...
Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
(0)
(0)